Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SynerG (specifically marketed as SynerG 6.0 by Innocutis, later acquired by Cipher Pharmaceuticals) is a multi-ingredient dietary supplement (MIDS) formulated to support hair, skin, and nail health, particularly in the context of thinning hair. The product is designed to address multiple pathways associated with hair loss, including hormonal balance, oxidative stress, and nutritional deficiencies. Its formulation typically includes a blend of botanical extracts and micronutrients such as biotin, zinc, saw palmetto (Serenoa repens), beta-sitosterol, pygeum africanum, pumpkin seed extract, and green tea extract. Saw palmetto and beta-sitosterol are included for their potential to inhibit 5-alpha-reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT), a primary driver of androgenetic alopecia. The supplement was primarily distributed through physician offices and dermatology clinics as a professional-grade nutraceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SynerG.